drugset
drugset / Trial / NCT06468098

A Study of IBI363 in Subjects With Advanced Malignancies

NCT06468098 ↗

Phase 1 Recruiting 556 enrolled Innovent Biologics (Suzhou) Co. Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multicenter Phase Ib study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced malignancies patients

Timeline

Start
2024-06-15
Primary completion
2025-06-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI363 Protein / enzyme biologic — —

Indications

cancer